Friday, November 9th, 2007...5:30 am
Cleveland BioLabs Founding Partner Cleveland Clinic Receives Department of Defense Grant to Study Protectans CBLB502 … (Marketwire via Yahoo! Finance)
Jump to Comments
Cleveland BioLabs Not Selected for Defense Contract Award (Marketwire via Yahoo! Finance) Cleveland BioLabs Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With … (Marketwire via Yahoo! Finance) Cleveland BioLabs to Present Protectan CBLB502 at 2007 BARDA Industry Day (Marketwire via Yahoo! Finance) Cleveland BioLabs Protectan CBLB502 Demonstrates Significant Reduction of Adverse Effects of Chemotherapeutic Drug in … (Marketwire via Yahoo! Finance) Cleveland BioLabs Recaps Development of Lead Compounds and Affirms Confidence in Competitive Position for Department … (Marketwire via Yahoo! Finance)
Cleveland BioLabs, Inc. today announced that its academic and founding partner, Cleveland Clinic, received a $1 million grant from the Department of Defense to conduct pre-clinical studies on two of the Company’s lead compounds, Protectan CBLB502 and Protectan CBLB612, for use in tourniquet and other ligation-reperfusion battlefield injuries where blood flow is stopped and then restored after a …
Full story at cleveland-akron news
Share your Opinion